Real-World, Long-Term Quality of Life Following Therapeutic OnabotulinumtoxinA Treatment.

CONCLUSION: MOBILITY is the largest prospective study to date to provide QoL data over a variety of therapeutic indications following treatment with onabotulinumtoxinA. Although the QoL burden varies by disease, data suggest that long-term treatment may help improve or maintain QoL over time. PMID: 27430524 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/27430524?dopt=Abstract

Source: The Canadian Journal of Neurological Sciences - July 18, 2016 Category: Neurology Authors: Jog M, Wein T, Bhogal M, Dhani S, Miller R, Ismail F, Beauchamp R, Trentin G Tags: Can J Neurol Sci Source Type: research